A couple of weeks or so ago, t4_malcontent posted a blog about Yellow Card reports. Within these reports, Armour Thyroid was included as a "single active constituent product". Of course, most people here probably know that Armour contains levothyroxine and liothyronine so that was an incorrect classification.
This was the blog:
Not liking things like this to be wrong, I contacted the MHRA and pointed out the problem. Today I received this email (suitably redacted):
Re: Levothyroxine ADRs
Thank you for recent enquiry regarding the Drug Analysis Print (DAP) for levothyroxine, specifically relating to the product Armour Thyroid.
I can confirm that you are correct in stating that the product Armour Thyroid contains the active substances levothyroxine and liothyronine. Thank you for bringing this error to our attention. Our record for Armour Thyroid has been amended and future DAPs for levothyroxine will state Armour Thyroid as a multi active constituent product.
Please accept our apologies for any inconvenience this has caused to you and do not hesitate to contact me if I can be of further assistance.
Associate Signal Assessor
Vigilance Risk Management of Medicines
So it is quite clear that reporting of issues does get things corrected.